What possible compounded semaglutide ban means for patients

The FDA declared the shortage of Novo Nordisk’s weight-loss drugs over, giving compounders until May to stop making alternatives. An industry group representing compounders is suing. Dr. Angela Fitch discusses what this means for patients.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *